Herantis Pharma telah menerima tanggapan positif dari FDA AS mengenai desain studi Fase 2a untuk HER-096, kandidat utama mereka untuk pengobatan penyakit Parkinson. FDA tidak memiliki kekhawatiran mengenai informasi kimia, manufaktur, dan kontrol (CMC) perusahaan atau paket data praklinis. Studi Fase 2a akan melibatkan sekitar 100 pasien Parkinson yang baru didiagnosis di Eropa, dengan tujuan mengevaluasi kemanjuran, keamanan, dan tolerabilitas HER-096. Herantis telah mengamankan lebih dari 50% pendanaan yang dibutuhkan untuk studi Fase 2 dan sedang mencari alternatif pembiayaan lebih lanjut.
Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended increasing the dose to 10 mg/kg for Cohort 2 in its ELEVATE-45-201 Phase 1/2 trial for Duchenne muscular dystrophy. This follows safety and pharmacokinetic r...
YieldMax® has declared monthly distributions for its Target 12™ ETFs, aiming for a 12% annual income. The ETFs include BIGY, RNTY, and SOXY, each with varying distribution rates and risks such as price participation limits and liquidity concerns. Inv...
Questrade has introduced Custom Indexing, Canada's first personalized index investing product that allows investors to create tailored index portfolios without management or trading fees. Investors can customize their portfolios by selecting from a b...
The European Union is set to propose tighter regulations for cloud computing services in major state tenders, aiming to reduce reliance on U.S. tech giants like Amazon, Microsoft, and Google. This move is part of the EU's Cloud and AI Development Act...
The global Mass Notification System (MNS) market is forecasted to grow from $28.88 billion in 2025 to $80.44 billion by 2030, at a CAGR of 22.7%. This surge is driven by stricter regulatory requirements for multi-channel emergency communication and t...
